Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $189,831.30 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 5,042 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $189,831.30. Following the completion of the transaction, the chief executive officer now directly owns 655,432 shares in the company, valued at $24,677,014.80. The trade was a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Twist Bioscience Stock Performance

TWST stock opened at $30.82 on Friday. The company has a 50 day moving average price of $38.63 and a 200 day moving average price of $43.65. Twist Bioscience Co. has a fifty-two week low of $30.72 and a fifty-two week high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock has a market capitalization of $1.85 billion, a PE ratio of -9.12 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Tuesday. The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday. Barclays cut their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Guggenheim reiterated a “buy” rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday. Finally, Robert W. Baird dropped their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.40.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently modified their holdings of TWST. ARK Investment Management LLC grew its holdings in Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock worth $245,045,000 after acquiring an additional 645,730 shares during the period. Vanguard Group Inc. boosted its position in shares of Twist Bioscience by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company’s stock worth $230,356,000 after purchasing an additional 60,276 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Geode Capital Management LLC increased its holdings in Twist Bioscience by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock valued at $63,895,000 after purchasing an additional 6,908 shares during the last quarter. Finally, First Light Asset Management LLC bought a new position in Twist Bioscience during the fourth quarter worth about $56,984,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.